TherOx gets FDA panel date
This article was originally published in The Gray Sheet
Executive Summary
FDA's Circulatory System Devices Panel will meet March 18 in Gaithersburg, Md., to vote on a pre-market approval application for the firm's Aqueous Oxygen System for acute myocardial infarction patients who have undergone successful revascularization up to six hours after symptom onset. The system is used to hyperoxygenate and reinfuse a patient's blood at the infarction site